Surfactant prevention of lung complications from cancer chemotherapy
AssigneeThe Penn State Research Foundation
InventorsJoanna Floros, David S. Phelps, Hamid A. Al-Mondhiry, Weixiong Huang, Guirong Wang
Life of this patent
Estimating the term…
Abstract
A means and method for treating pulmonary fibrosis in animals is described. The compositions include surfactant lipids in a pharmaceutically acceptable carrier. Surfactant lipids have been found to suppress the synergistic effect of bleomycin and SP-A in enhancing proinflammatory cytokine production. Surfactant lipids are also effective in the prevention and treatment of pulmonary fibrosis resulting from exposure to inflammatory agents affecting cytokine production.
Claims19
A composition for preventing and treating pulmonary fibrosis in animals, said composition comprising surfactant lipids.
A method of preventing and treating pulmonary fibrosis in animals comprising:
- administering to an animal a small but effective amount of a composition comprising surfactant lipids.
The method of 10 wherein the surfactant lipids are administered concurrently with an agent selected from the group consisting of bleomycin, nitrofurantoin, amiodarone, cyclophosphamide, and methotrexate.
A method of suppressing the additive or synergistic effect of bleomycin and SP-A on cytokine production in animals comprising:
- administering to the animal a composition comprising surfactant lipids.
A method of manufacturing a composition for prevention and treatment of pulmonary fibrosis in animals comprising:
- mixing a pulmonary fibrosis preventative or treatment effective amount of surfactant lipids with a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.